US4465670A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1982-07-23
•
Granted: 1984-08-14
•
Expires: 2002-07-23
Abstract
Abstract A method for the treatment of diseases such as systemic lupus erythematosus and primary glomerulonephritis by administering a γ-globulin having Fc fragment to patients suffering from such diseases in parenteral route (particularly intravenously) and a preparation useful for the treatment. The γ-globulin having Fc fragment is usually used in the form of a preparation thereof in admixture with a conventional liquid carrier on diluent for injection, including a plasmin-treated human γ-globulin preparation, a sulfonated human γ-globulin preparation and a polyethylene glycol-treated human γ-globulin preparation.
Inventors
- 👤 Tetsuzo Sugisaki
- 👤 Shinichi Morisue
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 00:59
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/06; C07K16/065; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/866; Y10S530/868
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
41 words
A method for the treatment of the diseases lupus erythematosus and primary glomerulonephritis, which consisting essentially of administering an amount of a γ-globulin having Fc fragment to a patient by parenteral route effective to dissolve the immune complexes inducing those diseases.
Claim 2
Independent Claim
41 words
A method for the treatment of the diseases lupus erythematosus and primary glomerulonephritis, which consisting essentially of administering an amount of a γ-globulin having Fc fragment to a patient by parenteral route effective to dissolve the immune complexes inducing those diseases.
Claim 3
Dependent Claim
25 words
A method according to claim 1, wherein the γ-globulin having Fc fragment is administered by intravenous injection in a dose of 10 to 500 mg/kg/day.
Claim 4
Dependent Claim
42 words
A method according to claim 1, wherein the γ-globulin having Fc fragment is used in the form of a preparation of 500 to 10,000 mg of a γ-globulin having Fc fragment in admixture of a conventional liquid carrier or diluent for injection.
Claim 5
Dependent Claim
15 words
A method according to claim 3, wherein the preparation is a plasmin-treated human γ-globulin preparation.
Claim 6
Dependent Claim
15 words
A method according to claim 3, wherein the preparation is a sulfonated human γ-globulin preparation.
Claim 7
Dependent Claim
16 words
A method according to claim 3, wherein the preparation is a polyethylene glycol-treated human γ-globulin preparation.
Claim 8
Dependent Claim
35 words
A method according to claim 1, wherein the γ-globulin, having Fc fragment, is a member selected from the group consisting of a plasmin-treated human γ-globulin, a polyethylene glycol-treated human γ-globulin, and a sulfonated human γ-globulin.
References Cited (Backward Citations)
US2543215A
Cited
US3763135A
Cited
US4059571A
Cited
US4093606A
Cited
US4165370A
Cited
US4124576A
Cited
US4296027A
Cited
US4322403A
Cited
US4256631A
Cited
US4329331A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-14 | 1988-02-13 | 1988-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-14 | 1992-02-13 | 1992-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-14 | 1996-02-13 | 1996-08-14 | $7700.00 | Window Closed / Lapsed |